Compare PLBC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | EDIT |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.9M | 432.8M |
| IPO Year | 2002 | 2016 |
| Metric | PLBC | EDIT |
|---|---|---|
| Price | $57.23 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $57.67 | $5.30 |
| AVG Volume (30 Days) | 64.2K | ★ 3.7M |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 1.38 | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $40.43 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $39.70 | $1.66 |
| 52 Week High | $57.51 | $4.54 |
| Indicator | PLBC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 68.07 | 50.25 |
| Support Level | $50.86 | $2.47 |
| Resistance Level | $57.51 | $3.27 |
| Average True Range (ATR) | 1.71 | 0.22 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 96.30 | 52.56 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.